Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report

Khalid Al-Baimani, Harman S. Sekhon, Paul Wheatley-Price

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC. Presentation of case: Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later. Discussion: It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis. Conclusion: This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.

Original languageEnglish
Pages (from-to)6-9
Number of pages4
JournalCancer Treatment Communications
Volume4
DOIs
Publication statusPublished - 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Adenocarcinoma
Recurrence
Protein-Tyrosine Kinases
anaplastic lymphoma kinase
Therapeutics

Keywords

  • ALK
  • NSCLC
  • Outcome
  • Relapse
  • Stage one

ASJC Scopus subject areas

  • Oncology

Cite this

Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years : Case report. / Al-Baimani, Khalid; Sekhon, Harman S.; Wheatley-Price, Paul.

In: Cancer Treatment Communications, Vol. 4, 2015, p. 6-9.

Research output: Contribution to journalArticle

@article{49a88be9950f40c3b677a034346f95cf,
title = "Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report",
abstract = "Introduction: About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC. Presentation of case: Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later. Discussion: It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis. Conclusion: This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.",
keywords = "ALK, NSCLC, Outcome, Relapse, Stage one",
author = "Khalid Al-Baimani and Sekhon, {Harman S.} and Paul Wheatley-Price",
year = "2015",
doi = "10.1016/j.ctrc.2015.03.001",
language = "English",
volume = "4",
pages = "6--9",
journal = "Cancer Treatment and Research Communications",
issn = "2213-0896",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years

T2 - Case report

AU - Al-Baimani, Khalid

AU - Sekhon, Harman S.

AU - Wheatley-Price, Paul

PY - 2015

Y1 - 2015

N2 - Introduction: About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC. Presentation of case: Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later. Discussion: It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis. Conclusion: This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.

AB - Introduction: About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC. Presentation of case: Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later. Discussion: It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis. Conclusion: This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.

KW - ALK

KW - NSCLC

KW - Outcome

KW - Relapse

KW - Stage one

UR - http://www.scopus.com/inward/record.url?scp=84947902007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947902007&partnerID=8YFLogxK

U2 - 10.1016/j.ctrc.2015.03.001

DO - 10.1016/j.ctrc.2015.03.001

M3 - Article

AN - SCOPUS:84947902007

VL - 4

SP - 6

EP - 9

JO - Cancer Treatment and Research Communications

JF - Cancer Treatment and Research Communications

SN - 2213-0896

ER -